Autopsy report · NCT00219765
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients
Cause of deathNo reason given
Life of this trial
- Registered 4 years 4 months after it had already started.
- Ran for about 4 years 8 months before it stopped.
- 30 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Poitiers University Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Imatinib mesylate 600 mg; Cytarabine; Daunorubicine
- Participants
- 30
- Sites
- 1
- Countries
- France
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.